Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients
Status In-Process Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu dopisy
Grantová podpora
CZ.10.03.01/00/22_003/0000003
European Union project LERCO
CZ.02.01.01/00/22_008/0004644
OP JAK SALVAGE, co-financed from the EU and the State budget
NU23-03-00374
Czech Health Research Council
MH CZ- DRO-FNOs/2022
Institutional support, University Hospital Ostrava
MH CZ-DRO- FNOs/2023
Institutional support, University Hospital Ostrava
MH CZ-DRO- FNOs/2024
Institutional support, University Hospital Ostrava
1/OR-FNO/2024
Institutional support, University Hospital Ostrava
e-INFRA CZ (ID:90254)
Ministry of Education, Youth and Sports of the Czech Republic
PubMed
39812365
PubMed Central
PMC11886492
DOI
10.1002/ajh.27590
Knihovny.cz E-zdroje
- Klíčová slova
- MRD, NGF, autografts, hematopoietic cell grafts, minimal residual disease, multiple myeloma, next generation flow cytometry,
- Publikační typ
- dopisy MeSH
Department of Flow Cytometry Spadia Lab Plc Ostrava Czech Republic
Department of Hematooncology Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Zobrazit více v PubMed
Vogel W., Kopp H. G., Kanz L., and Einsele H., “Myeloma Cell Contamination of Peripheral Blood Stem‐Cell Grafts Can Predict the Outcome in Multiple Myeloma Patients After High‐Dose Chemotherapy and Autologous Stem‐Cell Transplantation,” Journal of Cancer Research and Clinical Oncology 131, no. 4 (2005): 214–218. PubMed
Kopp H. G., Yildirim S., Weisel K. C., Kanz L., and Vogel W., “Contamination of Autologous Peripheral Blood Progenitor Cell Grafts Predicts Overall Survival After High‐Dose Chemotherapy in Multiple Myeloma,” Journal of Cancer Research and Clinical Oncology 135, no. 4 (2009): 637–642. PubMed
Pasvolsky O., Milton D. R., Rauf M., et al., “Impact of Clonal Plasma Cells in Autografts on Outcomes in High‐Risk Multiple Myeloma Patients,” Blood Cancer Journal 13, no. 1 (2023): 68. PubMed PMC
Kostopoulos I. V., Eleutherakis‐Papaiakovou E., Rousakis P., et al., “Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next‐Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients,” Cancers 13, no. 16 (2021): 4047. PubMed PMC
Urushihara R., Takezako N., Yoroidaka T., et al., “Eight‐Color Multiparameter Flow Cytometry (EuroFlow‐NGF) is as Sensitive as Next‐Generation Sequencing in Detecting Minimal/Measurable Residual Disease in Autografts of Patients With Multiple Myeloma,” EJHaem 4, no. 1 (2023): 184–191. PubMed PMC
Sonneveld P., Dimopoulos M. A., Boccadoro M., et al., “Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,” New England Journal of Medicine 390, no. 4 (2024): 301–313. PubMed
